- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
CAT quits plans for scar-tissue treatment
Cambridge, England—Cambridge AntibodyTechnology's (CAT) potential treatment for improving trabeculectomy outcomes has failed to meet the primary endpoint in its second pivotal clinical trial and will be discontinued.
Cambridge, England-Cambridge AntibodyTechnology's (CAT) potential treatment for improving trabeculectomy outcomes has failed to meet the primary endpoint in its second pivotal clinical trial and will be discontinued. The treatment, called Trabio, referred to a human monoclonal antibody designed to neutralize transforming growth factor beta-2, a protein produced in response to eye injury and believed to be responsible for the growth of excessive scar tissue after glaucoma surgery.
Results from earlier clinical trials showed lower IOP and reduced postoperative intervention following Trabio treatment. However, the international phase III trial results are consistent with the first pivotal clinical trial, and the company is terminating further development.
